

DAFTAR PUSTAKA

1. Mittal R, Lisi C V., Gerring R, Mittal J, Mathee K, Narasimhan G, et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media. *J Med Microbiol.* 2015;64(10):1103–16.
2. Castle JT. Cholesteatoma Pearls: Practical Points and Update. *Head Neck Pathol.* 2018;12(3):419–29.
3. Rutkowska J, Özgürin N, Olszewska E. Cholesteatoma definition and classification: A literature review. *J Int Adv Otol.* 2017;13(2):266–71.
4. Kuo C-L. Recent Advances in Understanding the Pathogenesis of Acquired Cholesteatoma. *Recent Adv Otolaryngol Neck Surg* (Volume 5). 2016;(May):167–167.
5. Bennett M, Warren F, Jackson GC, Kaylie D. Congenital Cholesteatoma: Theories, Facts, and 53 Patients. *Otolaryngol Clin North Am.* 2006;39(6):1081–94.
6. Xie S, Xiang Y, Wang X, Ren H, Yin T, Ren J, et al. Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways. *Laryngoscope.* 2016;126(8):1923–30.
7. Pusalkar AG. Cholesteatoma and Its Management. *Indian J Otolaryngol Head Neck Surg.* 2015;67(3):201–4.
8. Jackler RK, Santa Maria PL, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. *Laryngoscope.* 2015;125(S4):S1–14.
9. Hamed MA, Nakata S, Sayed RH, Ueda H, Badawy BS, Nishimura Y, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future prospectives. *Clin Exp Otorhinolaryngol.* 2016;9(4):298–308.
10. Olszewska E, Wagner M, Bernal-Sprekelsen M, Ebmeyer J, Dazert S, Hildmann H, et al. Etiopathogenesis of cholesteatoma. *Eur Arch Oto-Rhino-Laryngology.* 2004;261(1):6–24.
11. Meyer T, Strunk C, Lambert P. Cholesteatoma. In: Johnson J, Rosen C, editors. *Bailey's Head & Neck Surgery Otolaryngology Vol 2.* 5 th editi. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 2433–43.
12. Wageih Felfela GM. Ear Anatomy. *Glob J Otolaryngol.* 2017;4(1):22–39.
13. Macias JD, Gerkin RD, Locke D, Macias MMP. Differential gene expression in cholesteatoma by DNA chip analysis. *Laryngoscope.* 2013;123(SUPPL.5):1–21.
14. Gazel A, Nijhawan RI, Walsh R, Blumenberg M. Transcriptional profiling defines the roles of ERK and p38 kinases in epidermal keratinocytes. *J Cell Physiol.* 2008;215(2):292–308.
15. Pivarcsi A, Müller A, Hippe A, Rieker J, Van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. *Proc Natl Acad Sci U S A.* 2007;104(48):19055–60.

16. Karakawa M, Komine M, Hanakawa Y, Tsuda H, Sayama K, Tamaki K, et al. CCL27 is downregulated by interferon gamma via epidermal growth factor receptor in normal human epidermal keratinocytes. *J Cell Physiol*. 2014;229(12):1935–45.
17. Menglu Z, Yongtuan L. Expression of chemokine ligand 27 in secondary middle ear cholesteatoma. *J Shandong Univ (Otolaryngology Ophtalmol)*. 2017;31(6):46–8.
18. Edward Y, Decroli E, Ali H, Tjong DH. Expression of ccl27 in middle ear cholesteatoma. *Open Access Maced J Med Sci*. 2021;9(T3):240–3.
19. Frickmann H. Cholesteatoma ? A Potential Consequence of Chronic Middle Ear Inflammation. *Otolaryngology*. 2012;02(03).
20. Dihl C, Goldenberg D, Goldstein B, Isaacson, JE, Lesnik G, Levi A. Otology and Neurootology. In: Goldenberg D, Goldstein B, editors. *Handbook of Otolaryngology Head and Neck Surgery*. second edi. New York: Thieme Publisher; 2018. p. 127–45.
21. Morris P. Clinical Evidence Handbook. *Am Fam Physician*. 2013;88(10):694–6.
22. Yung M, Tono T, Olszewska E, Yamamoto Y, Sudhoff H, Sakagami M, et al. EAONO/JOS joint consensus statements on the Definitions, Classification and Staging of Middle Ear Cholesteatoma. *J Int Adv Otol*. 2017;13(1):1–8.
23. Dornelles C, da Costa SS, Meurer L, Schweiger C. Some considerations about acquired adult and pediatric cholesteatomas. *Braz J Otorhinolaryngol*. 2005;71(4):536–45.
24. Louw L. Acquired cholesteatoma pathogenesis: Stepwise explanations. *J Laryngol Otol*. 2010;124(6):587–93.
25. Kim HJ, Tinling SP, Chole RA. Expression patterns of cytokeratins in retraction pocket cholesteatomas. *Laryngoscope*. 2001;111(6):1032–6.
26. Kanemaru SI, Kikkawa Y, Omori K, Ito J. Bone destructive mechanisms of cholesteatoma. *Laryngoscope*. 2010;120(SUPPL. 3):68.
27. Lim HD, Robert Lane J, Canals M, Stone MJ. Systematic assessment of chemokine signaling at chemokine receptors ccr4, ccr7 and ccr10. *Int J Mol Sci*. 2021;22(8):9-14
28. Schürmann M, Oppel F, Shao S, Volland-Thurn V, Kaltschmidt C, Kaltschmidt B, et al. Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism. *Cell Commun Signal*. 2021;19(1):1–15.
29. Lin F-C, Young HA. The talented interferon-gamma. *Adv Biosci Biotechnol*. 2013;04(07):6–13.
30. Louis S. *Growth Factor Handbook*. Gold Biotechnology. London;2013:1–23.
31. Xie S, Wang X, Ren J, Liu W. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. *Eur Arch Oto-Rhino-Laryngology*. 2017;274(5):207:1–8.
32. Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X, et al. Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium. *Eur Arch Oto-Rhino-Laryngology*.

- 2014;271(2):265–73.
- 33. Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. *Physiol Rev.* 2016;96(3):1025–69.
 - 34. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers (Basel).* 2017;9(5):1–45.
 - 35. Jin BJ, Min HJ, Jeong JH, Park CW, Lee SH. Expression of EGFR and microvessel density in middle ear cholesteatoma. *Clin Exp Otorhinolaryngol.* 2011;4(2):67–71.
 - 36. Murphy P. Chemokines and chemokine receptors. Fifth Edit. Clinical Immunology. Elsevier Ltd; 2019. 157–70.
 - 37. Lopes-Marques M, Alves LQ, Fonseca MM, Secci-Petretto G, Machado AM, Ruivo R, et al. Convergent inactivation of the skin-specific C-C motif chemokine ligand 27 in mammalian evolution. *Immunogenetics.* 2019;71(5–6):363–72.
 - 38. Riis JL, Johansen C, Vestergaard C, Bech R, Kragballe K, Iversen L. Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. *Exp Dermatol.* 2011;20(10):789–94.
 - 39. Gudjonsson J, Ding J, Johnston A, Tejasvi T, Guzman A, Nair R, et al. Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models. *J Invest Dermatol.* 2010;130(7):1829–40.
 - 40. Edward Y, Munilson J, Rosalinda R, Ali H, Irfandy D, Swanda D. Expression of tumor necrosis factor- α and interleukin-6 in chronic suppurative otitis media. *Turkish J Immunol.* 2019;7(1):1–5.
 - 41. Agarwal S, Krishnamurthy K. Histology, Skin. Virginia: StatPearls Publishing; 2022. 1–8.
 - 42. Ansari A, Tariq, Muhammad A, Sadiq, Nazia M. Histology, Ear. Louisville: StatPearls Publishing; 2022. 1–8.
 - 43. Dahlan S. Menggunakan rumus besar sampel secara benar. In: Besar Sampel Dan Cara Pengambilan Sampel. 3rd ed. Jakarta: Salemba Medika; 2013:35–72.
 - 44. Sastroasmoro S, Ismael S. Perkiraan besar sampel. In: Dasar Dasar Metodologi Penelitian Klinis. 3rd ed. Jakarta: Sagung Seto; 2008:302–32.
 - 45. Rosito LPS, Silva MN, Selaimen FA, Jung Y, Pauletti MGT, Jung LP, et al. Characteristic og 419 patients with acquired middle ear cholesteatoma. *Brazilian Journal of Otolaryngology.* 2017; 83(2): 126-31.
 - 46. Khan AU, Khan Q, Ahmed n, Ullah I, Khan MF. Clinicaal Findings and Diagnosis if Cholesteatoma. *PJMHS.* 2013; 7(4): 1184-9.
 - 47. Yamashita K, Yoshiura T, Hiwatashi A, Tuvshinjargal D, Kamano H, Shiratsuchi, et al. Contributing Factors in the Pathogenesis of Acquired Cholesteatoma: Size Analysis Based on MDCT. *AJR.* 2011; 196: 1172-5.
 - 48. Baig MM, Ajmal M, Saeed I, Fatima S. Prevalence of Colesteatoma and its Complications in Patients of Chronic Suppurative Otitis Media. *Journal of*

- Rawalpindi Medical College. 2011; 15(1): 16-7.
49. Li J, Jufas N, Forer M, Patel N. Incidence and trends of middle ear cholesteatoma surgery and mastoidectomy in Australia- a national hospital morbidity database analysis. *Laryngoscope Investigative Otolaryngology*. 2022; 7: 210-8.
50. Rosito LS, Netto LFS, Teixeira AR, da Costa SS. Classification of Cholesteatoma According to Growth Patterns. *JAMA Otolaryngol Neck Surg*. 2016 Feb 1;142(2):168-73.
51. Shinnabe A, Hara M, Hasegawa M, Matsizawa S, Kanazawa H, Yoshida N, Iino Y. Clinical Characteristics and Surgical Benefits and Problems of Chronic Otitis Media and Middle Ear Cholesteatoma in Elderly Patients Older than 70 years. *Otology and Neurotology*. 2012; 33: 1213-7.
52. Chang P, Kim S. Cholesteatoma- diagnosing the unsafe ear. *Australian Family Physician*. 2008; 37(8): 631-6.
53. Bhutta M, Williamson IG, Sudhof HH. Cholesteatoma. *BMJ*. 2011; 342: 596-8.
54. Bujia J, Kim C, Holly A, Sudhoff H, Ostos P, Kastenbauer E. Epidermal Growth Factor Receptor (EGF-R) in Human Middle Ear Cholesteatoma: An Analysis of Protein Production and Gene Expression. *The American Journal of Otology*. 1996; 17: 203-6.
55. Kuo C. Etiopathogenesis of Acquired Cholesteatoma: Prominent Theories and Recent Advances in Biomolecular Research. *The Laryngoscope*. 2014; 1-7.
56. Bujia J, Holly A, Schilling V, negri B, Pitzke P, Schulz P. Aberrant Expression of Epidermal Growth Factor Receptor in Aural Cholesteatoma. *Laryngoscope*. 1993; 103: 326-9.
57. Kojima H, Shiwa M, Kamide Y, Moriyama H. Expression and localization of mRNA for Epidermal Growth Factor and Epidermal Growth Factor Receptor in Human Cholesteatoma. *Acta Otolaryngol*. 1994; 114: 423-9.
58. Hu J, Kim H, Lim H, Cho Y. Expression of Epidermal Growth Factor Receptor Gene in Aural Cholesteatoma Measured by Reverse Transcription-Polymerase Chain Reaction. *Korean J Audiol*. 2000; 4(1): 14-20.
59. Ottaviani F, Neglia CB, Berti E. Cytokines and Adhesion Molecules in Middle Ear Cholesteatoma. A Role in Epithelial Growth?. *Acta Otolaryngol*. 1999; 119: 462-7.
60. Maniu A, Harabgiu O, Schrepler MP, Catana A, Fanuta B, Mogoanta CA. Molecular biology of cholesteatoma. *Rom J Morphol Embryol*. 2014; 55(1): 7-13.
61. Kaya İ, Avcı CB, Şahin FF, Özateş NP, Sezgin B, Kurt CC, et al. Evaluation of significant gene expression changes in congenital and acquired cholesteatoma. *Mol Biol Rep*. 2020;47(8):6127–33.
62. Hsu Y, Chai C, Lee K, Wang L, Wu S, Kuo W, Tsai S. Expression of Epidermal Growth Factor Receptor in Human Middle Ear Cholesteatoma. *Kaohsiung J Med Sci*. 2003; 19: 497-502.
63. Alves AL, Pereira CSB, Carvalho MFP, Fregnani JHTG, Ribeiro FQ. EGFR expression in acquired middle ear cholesteatoma in children and adults. *Eur J Pediatr*. 2012; 171: 307-10.

64. Chi H, Ho K, Chai C, Ta C, Wang L, Lee K, et al. Epidermal Growth Factor in Middle Ear Cholesteatoma. *J Med Sci*. 2004; 20: 6-11.
65. Yetiser S, Satar B, Aydin N. Expression of Epidermal Growth factor, Tumor Necrosis Factor- α , and Interleukin-1 α in chronic Otitis Media with or without Cholesteatoma. *Otology and Neurotology*. 2002; 23: 647-52.
66. Liu W, Ren H, Ren J, Yin T, Hu B, Xie S, et al. The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma. *Mediators Inflamm*. 2013;5(1):1–10
67. Thorup MB, Munk M, Poulsen SS, Gaihede MG, Sorensen BS, Ovesen T. Expression of the epidermal growth factor system in human middle ear cholesteatoma. *Acta Oto-Laryngologica*. 2014; 134: 124-34.

